

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
EHE Triannual Module .....	47	3	141	1	141
Total .....	47	.....	141	.....	141

HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

**Maria G. Button,**  
 Director, Division of the Executive Secretariat.  
 [FR Doc. 2019-22395 Filed 10-11-19; 8:45 am]

**BILLING CODE 4165-15-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Health Resources and Services Administration**

**Notice of Single Source Award to the Rural Communities Opioid Response Program—Technical Assistance**

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** The Rural Communities Opioid Response Program—Technical Assistance (RCORP-TA), program supports rural consortiums and opioid recipients that provide treatment for and prevention of substance use disorder with a focus on opioid use disorder. The TA efforts will enhance the organizational and infrastructural capacity of multi-sector consortiums at the community, county, state, and/or regional levels. The overall goal is the reduction of morbidity and mortality associated with opioid overdoses in high-risk rural communities. The RCORP-TA award recipient provides resources and expertise in support of the execution of the following focus areas: (1) Prevention—reducing the occurrence of opioid use disorder (OUD) among new and at-risk users as well as fatal opioid-related overdoses through community and provider education and harm reduction measures including the strategic placement of overdose

reversing devices, such as naloxone; (2) treatment—implementing or expanding access to evidence-based practices for opioid addiction/OD treatment such as medication-assisted treatment, including developing strategies to eliminate or reduce treatment costs to uninsured and underinsured patients; and (3) recovery—expanding peer recovery and treatment options to help people start and stay in recovery.

The RCORP-TA initiative is part of a multi-year, opioid focused effort by HRSA that will include: Improving access to and recruitment of new substance use disorder providers; building sustainable treatment resources; increasing the use of telehealth; establishing cross-sector community partnerships; implementing new models of care, including integrated behavioral health; and providing technical assistance.

**SUPPLEMENTARY INFORMATION:**

*Intended Recipient of the Award:* JBS International, Inc. (U6BRH32364).

*Amount of Award:* \$3,000,000.

*Project Period:* September 30, 2019–September 29, 2020.

*CFDA Number:* 93.912.

**Authority:** Public Health Service Act, Section 330A (f) (42 U.S.C. 254c (f)), as amended.

*Justification:* Additional funding will be awarded annually through FY 2022 contingent on satisfactory performance of the recipient, and continued availability of funds.

The RCORP-TA program was announced under HRSA-18-124. In FY 2018, HRSA funded this program at up to \$3,000,000 per year to one awardee, JBS International, Inc., for a period of performance for up to 4 years. RCORP-TA program was competed in late FY 2018. At the time of the award, RCORP-TA recipient was expected to provide technical assistance to 75 opioid award recipients. The current RCORP-TA recipient is expected to support approximately 318 opioid award recipients. As a result of this increase in opioid award recipients, the RCORP-TA recipient will need additional funds to expand its capacity to provide TA services. Supplemental funding is

required for the current RCOPR-TA award recipient to provide TA services to the additional 243 opioid award recipients. These additional funds will enable the current recipient to provide high quality TA.

Further information on the Telehealth Focused Rural Health Research Center is available at: <https://www.hrsa.gov/ruralhealth/programopportunities/fundingopportunities/default.aspx?id=482de32c-8b8d-4960-bb86-caad8c9d6905>

**FOR FURTHER INFORMATION CONTACT:**

Marcia Colburn, Program Coordinator, RCORP-TA, (301) 443-3261, [MColburn@hrsa.gov](mailto:MColburn@hrsa.gov).

Dated: October 4, 2019.

**Thomas J. Engels,**  
 Acting Administrator.

[FR Doc. 2019-22434 Filed 10-11-19; 8:45 am]

**BILLING CODE 4165-15-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

[Document Identifier: OS-0990-xxxx]

**Agency Information Collection Request. 60-Day Public Comment Request**

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.

**DATES:** Comments on the ICR must be received on or before December 16, 2019.

**ADDRESSES:** Submit your comments to [Sherrette.Funn@hhs.gov](mailto:Sherrette.Funn@hhs.gov) or by calling (202) 795-7714.

**FOR FURTHER INFORMATION CONTACT:**

When submitting comments or requesting information, please include the document identifier 0990-New-60D, and project title for reference, to Sherrette Funn, the Reports Clearance Officer, [Sherrette.funn@hhs.gov](mailto:Sherrette.funn@hhs.gov), or call 202-795-7714.

**SUPPLEMENTARY INFORMATION:** Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

*Title of the Collection:* Medical Countermeasures.gov.

*Type of Collection:* OMB No. 0990-0323—Extension—

*Abstract:* The Office of the Assistant Secretary for Preparedness and Response (ASPR), Office of the Biomedical Advanced Research and Development Authority (BARDA), is requesting an approval on an extension by OMB on a currently approved information collection. The purpose of this collection is, in order to route product developers to the most appropriate personnel within the Department of Health and Human Services (HHS), HHS collects some basic information about the company's product through Medical Countermeasures.gov. Using this

information and a routing system that has been developed with input from participating agencies within HHS, including the Office of the Assistant Secretary for Preparedness and Response (ASPR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH), Medical Countermeasures.gov routes the meeting request to the appropriate person within HHS. ASPR is requesting an extension by OMB for a three-year clearance.

*Type of respondent:* Developers of medical countermeasures to naturally occurring and intentional public health threats visit the site on a monthly basis.

**ANNUALIZED BURDEN HOUR TABLE**

Forms (if necessary)	Respondents (if necessary)	Number of respondents	Number of responses per respondent	Average burden per response	Total burden hours
Meeting Request .....	Developers of medical countermeasures to naturally occurring and intentional public health threats..	245	1	10/60	41
Total .....	.....	.....	.....	.....	41

**Terry Clark,**  
*Asst Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.*  
 [FR Doc. 2019-22416 Filed 10-11-19; 8:45 am]  
**BILLING CODE 4150-04-P**

*Time:* 8:00 a.m. to 5:00 p.m.  
*Agenda:* To review and evaluate grant applications.  
*Place:* Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.  
*Contact Person:* Yasuko Furumoto, Ph.D., Scientific Review Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 6701 Democracy Blvd., Room 820, Bethesda, MD 20817, 301-827-7835, [yasuko.furumoto@nih.gov](mailto:yasuko.furumoto@nih.gov).

*Contact Person:* Yin Liu, Ph.D., MD, Scientific Review Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 6701 Democracy Blvd., Room 824, Bethesda, MD 20817, 301-594-8919, [liuy@mail.nih.gov](mailto:liuy@mail.nih.gov).  
 (Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: October 8, 2019.

**Sylvia L. Neal,**  
*Program Analyst, Office of Federal Advisory Committee Policy.*  
 [FR Doc. 2019-22382 Filed 10-11-19; 8:45 am]  
**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel: T32 Special Emphasis Panel.  
*Date:* October 29, 2019.

*Name of Committee:* National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel: AMS Member Conflict.  
*Date:* October 31, 2019.

*Time:* 11:00 a.m. to 12:00 p.m.  
*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Arthritis and Musculoskeletal and Skin Diseases, 6701 Democracy Boulevard, Room 818, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Kathy Salaita, SCD, Chief, Scientific Review Branch, DHHS/NIH/NIAMS, One Democracy Plaza, Suite 800, 6701 Democracy Blvd. MSC 4872, Bethesda, MD 20892, 301-594-5033, [Kathy.Salaita@nih.gov](mailto:Kathy.Salaita@nih.gov).

*Name of Committee:* National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel: Rare Diseases SBIR Review Meeting.  
*Date:* November 22, 2019.

*Time:* 8:00 a.m. to 5:00 p.m.  
*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Arthritis and Musculoskeletal and Skin Diseases, 6701 Democracy Boulevard, Bethesda, MD 20892.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Center for Scientific Review; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material,